By Gustavo Leite Neves da Luz
On 9 October 2026, the Parties to the London Convention and Protocol (LC/LP), the treaties regulating dumping at sea, adopted three assessment frameworks at the International Maritime Organization (IMO). They revised the framework for research involving ocean fertilisation and adopted new ones for ocean alkalinity enhancement and ocean sinking of biomass. The frameworks guide authorities in assessing whether a proposal qualifies as legitimate scientific research and whether its environmental risks are acceptable (IMO meeting summary).
These techniques are being explored as forms of marine carbon dioxide removal (mCDR), which could contribute to climate change mitigation by removing carbon dioxide from the atmosphere and storing the resulting carbon using the ocean. Ocean fertilisation adds nutrients to stimulate phytoplankton growth. Ocean alkalinity enhancement adds alkaline substances to increase seawater’s capacity to absorb carbon dioxide. Biomass sinking places organic material in the ocean with the aim of storing carbon. Field trials can help establish whether these techniques work and how they affect marine ecosystems (IMO overview).
The number of mCDR start-ups has grown rapidly, and some seek to finance their activities by selling credits or agreeing to sell them in advance. A carbon removal credit generally represents one tonne of carbon dioxide removed from the atmosphere. A pre-purchase agreement commits the buyer to buying credits expected to be issued later. When the credits are to come from a field trial, a finding of little or no removal can answer the scientific question while leaving the buyer without the credits it expected (German Environment Agency, 2025, section 2 and UN webinar on carbon markets, p. 16).
Can a field trial, an experiment conducted at sea, qualify as legitimate scientific research when its funding depends on selling the carbon credits it generates?
This post argues that the sale of credits from the trial raises a question of direct financial gain even when the research itself is scientifically independent.
Scientific independence and direct financial gain
In 2008, the Parties agreed that ocean fertilisation should be allowed only as legitimate scientific research. In 2023, they called for deferring activities beyond legitimate scientific research for the other marine geoengineering techniques under evaluation, which included ocean alkalinity enhancement and biomass cultivation for carbon removal. The 2013 amendment to the London Protocol would establish a treaty-based permitting regime for listed activities. It has yet to enter into force, and its Annex 4 lists only ocean fertilisation (Resolution LC-LP.1(2008), paras 7–8, 2023 statement, Resolution LP.4(8), Annex 4 and IMO status).
The 2010 ocean fertilisation framework considers financing when authorities first assess whether a proposal has the attributes of scientific research. The design, conduct and outcomes of the study should remain free from economic influence. The framework also calls for excluding financial or economic gain arising directly from the trial or its results. It expressly accommodates payments for services that support the trial and future financial benefits from patented technology (2010 framework, sections 2.1–2.2.2).
The 2013 amendment takes the same approach. Each of the three drafts tabled for the October meeting included both criteria (2013 amendment, Annex 5, para. 8.4 and drafts LC 48/5, LC 48/5/1 and LC 48/5/2, para. 3.3.1).
In July 2026, a majority of delegations in the Legal Intersessional Correspondence Group considered sales or pre-sales of credits inconsistent with paragraph 8.4, particularly where they linked financial incentives to expected results. Some delegations favoured examining the circumstances and safeguards case by case. The group recorded no common interpretation at that stage. In their account of the October decision, the Center for International Environmental Law and Friends of the Earth US read the adopted frameworks as excluding projects that generate or sell carbon credits (LC 48/5/4, paras 44–48 and joint account of the October decision).
What the funding agreement buys
Suppose a team proposes a field trial of ocean alkalinity enhancement. A public agency or a foundation could offer a research grant to pay for sampling and analysis. Payments can depend on completing the work and submitting a report, even if the trial finds little removal. A grant on those terms can satisfy the financial criteria if the research remains independent of economic interests. A foundation could even finance such a grant with money from credit sales by an unrelated project. The authority would still examine whether the terms give the funder influence over this trial or a right to its credits.
A payment to a laboratory for analysing samples falls within the allowance for supporting services. The laboratory earns its fee by doing the analysis, whatever the results show.
An investor could help finance the trial by buying a share of the company, with any credits from the trial outside the transaction. If the investor has a right to approve the site or the amount of material released, that term would matter to the assessment of scientific independence.
A contract for future credits from that same trial makes its removals the subject of the sale. A buyer can pay upfront or commit to paying on delivery. On the stricter reading, the sale would fail the direct-gain criterion even if all the money went towards research costs. Independent peer review can protect scientific decisions while leaving the sale subject to that separate criterion (for payment models, see Frontier’s funding and purchase tracks).
A harder case is a grant that also gives the funder an option to buy credits from a separate project at a later stage. The authority would need to identify which activity would generate the credits and what triggers the option. A clause that activates the option only if the field trial meets a removal target could influence how the trial is designed or how its results are reported. If the option also covers credits attributable to the trial itself, the entitlement raises a question of direct gain.
Authorities should examine the funding agreement alongside the research plan at the proposal stage. A commitment to deliver a minimum number of credits could affect the amount of material released or the duration of a trial. The proposed scale should be justified by the scientific question. If the contract requires repayment of an advance when too few credits are delivered, the authority should ask whether funds will still be available for monitoring. The October drafts ask what financial resources will be available before work starts (draft framework for ocean alkalinity enhancement, para. 3.3.1 and Appendix 1, para. 1.1.3).
Isometric’s methodology for crediting ocean alkalinity enhancement from coastal outfalls requires proponents to obtain permits from the relevant authorities. Those authorities can examine the funding agreement before a certifier verifies any removals (Isometric, section 6.2).
Research purposes across different regimes
In Whaling in the Antarctic, the International Court of Justice read Article VIII(2) of the Whaling Convention as permitting the sale of meat incidental to research whaling under a special permit. It held that financing research could not justify lethal sampling on a scale greater than was reasonable in relation to the research objectives. Applied to a field trial, that reasoning directs attention to the scientific justification for its scale. The LC/LP criteria add a separate inquiry into gain from selling the results (judgment, para. 94).
The Parties to the Convention on Biological Diversity addressed offset sales directly in relation to ocean fertilisation. Their 2008 decision asks that small scientific studies in coastal waters be carried out without generating and selling carbon offsets or serving other commercial purposes (Decision IX/16 C, para. 4).
Conclusion
A decision on whether a field trial qualifies as legitimate scientific research should explain separately how its financing bears on scientific independence and direct financial gain. If a contractual entitlement to credits from the trial is incompatible with the applicable criteria, the proponent may need to revise the agreement or secure funding on different terms before the trial can be authorised as research.